Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Rare Disease Pharmaceutical Service Market Forecast: What Market Value Is Expected By 2030?
The pharmaceutical service market focused on rare diseases has experienced rapid expansion in recent years. Its value is projected to rise from $133.4 billion in 2025 to $150.96 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.2%. This historical growth has been driven by an increase in orphan drug development initiatives, higher rates of rare disease diagnoses, an expanding infrastructure for clinical research, more regulatory incentives aimed at rare conditions, and greater participation from specialized service providers.
Over the next several years, the market for rare disease pharmaceutical services is anticipated to experience swift expansion. By 2030, it is projected to reach $245.14 billion, advancing at a compound annual growth rate (CAGR) of 12.9%. This forecasted growth is driven by several factors, including a greater reliance on outsourcing for rare disease development activities, the growing adoption of digital clinical trial platforms, an expanding global pipeline for rare disease treatments, an increased emphasis on generating real-world evidence, and a heightened need for specialized regulatory expertise. Key developments shaping this period include a rising demand for comprehensive rare disease services, an intensified focus on providing end-to-end support for drug development, a shift toward patient-centric care models, an expansion of services related to regulatory and market access, and the enhanced utilization of data-driven clinical management approaches.
Download A Free Sample Report For Comprehensive Market Insights:
Rare Disease Pharmaceutical Service Market Demand Drivers: What Is Fueling Industry Growth?
Advances in genomics, biomarker research, and data analytics are driving the increasing adoption of personalized medicine, which is anticipated to boost the rare disease pharmaceutical service market. Personalized medicine involves crafting medical treatments according to an individual’s genetic profile, thereby enhancing effectiveness and minimizing side effects, allowing it to address unmet patient needs more precisely than standard one-size-fits-all approaches. Pharmaceutical services contribute by developing targeted therapies, utilizing genetic and biomarker information, and offering customized treatment solutions tailored to each patient’s distinct requirements. For example, the Personalized Medicine Coalition, a US-based non-profit, reported in February 2024 that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 approvals in 2022. Consequently, the expansion of personalized medicine is fostering growth in the rare disease pharmaceutical service market.
Rare Disease Pharmaceutical Service Market Segment Analysis And Revenue Opportunities
The rare disease pharmaceutical service market covered in this report is segmented –
1) By Types: Drug Discovery, Clinical Trials, Other Types
2) By Application: Congenital And Genetic Diseases, Tumors And Cancer, Endocrine Diseases
3) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutions, Hospitals And Specialty Clinics, Contract Research Organizations (CROs) And Contract Development And Manufacturing Organizations (CDMOs), Diagnostic Laboratories And Genetic Testing Centers
Subsegments:
1) By Drug Discovery: Target Identification And Validation, Preclinical Research And Toxicology Studies, Biomarker Discovery And Validation, Genomic And Proteomic Analysis, Computational Drug Design And Modeling, High-Throughput Screening (HTS), Lead Optimization And Candidate Selection
2) By Clinical Trials: Clinical Trial Design And Protocol Development, Patient Recruitment And Retention, Site Management And Monitoring, Regulatory Affairs And Compliance Support, Data Management And Biostatistics, Pharmacovigilance And Safety Monitoring, Real-World Evidence (RWE) And Post-Marketing Studies
3) By Other Types: Market Access And Pricing Strategy, Health Economics And Outcomes Research (HEOR), Regulatory Affairs And Compliance Services, Manufacturing And CMC (Chemistry, Manufacturing, and Controls) Support, Medical Affairs And Scientific Communication, Post-Marketing Surveillance, Consulting And Strategic Advisory
Rare Disease Pharmaceutical Service Market Innovation Trends: Which Developments Are Transforming The Industry?
Leading firms within the rare disease pharmaceutical services sector are intensifying their efforts to develop novel therapeutic strategies, including the use of acetylleucine, with the goal of boosting treatment efficacy, improving patient well-being, and filling gaps in care for uncommon neurological and metabolic conditions. Acetylleucine, a modified form of the amino acid N-acetyl-L-leucine, serves as a medicinal agent designed to enhance motor abilities, balance, and overall neurological health in those affected. A key example occurred in September 2024, when IntraBio, a US-based biotechnology company, secured FDA approval for AQNEURSA, which stands as the first standalone therapy for Niemann-Pick Disease Type C—a rare and life-threatening neurodegenerative disorder. This achievement is particularly notable because the therapy produced swift and clinically significant improvements in neurological signs, delivering a transformative treatment option for both children and adults coping with this rare illness.
Rare Disease Pharmaceutical Service Market Leading Players Shaping Industry Direction
Major companies operating in the rare disease pharmaceutical service market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Chiesi Farmaceutici S.p.A., Recordati Industria Chimica e Farmaceutica S.p.A., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Travere Therapeutics Inc., Sciensus Healthcare Ltd., SOM Innovation Biotech S.L.
Access The Complete Rare Disease Pharmaceutical Service Market Report:
Rare Disease Pharmaceutical Service Market Largest Region By Revenue And Market Share
North America was the largest region in the rare disease pharmaceutical service market in 2025. The regions covered in the rare disease pharmaceutical service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model